妇科肿瘤协作组第五届卵巢癌共识会议:复发性疾病
本文报告了2015年11月在日本东京召开的第五届卵巢癌共识会议(OCCC)关于复发性卵巢癌(ROC)的共识声明,围绕临床试验的亚组划分、对照臂选择与终点设置三个问题给出推荐。共识以治疗间歇(TFI)取代无铂间歇(PFI)进行分层,并明确铂类适用与否时的对照臂方案及总生存期与无进展生存期的优先顺序。
要点
- 以治疗间歇(TFI)替代无铂间歇(PFI)用于复发性卵巢癌临床试验的亚组划分。
- 铂类为最佳选择时,对照臂为含铂方案联合或不联合抗血管生成药或PARP抑制剂。
- 预期中位总生存期≤12个月者首选总生存期,>12个月者首选无进展生存期。
核心结论
- 共识以治疗间歇(TFI)替代历史性的无铂间歇(PFI)用于复发性卵巢癌临床试验的亚组划分。
- 铂类为最佳选择时对照臂为含铂方案联合或不联合抗血管生成药或PARP抑制剂;否则对照臂可为非铂单药或联合方案。
- 预期中位总生存期≤12个月者首选总生存期,>12个月者首选无进展生存期,且无进展生存期不能作为唯一终点。
研究设计与样本
- 妇科肿瘤协作组第五届卵巢癌共识会议于2015年11月在日本东京召开,本文报告复发性卵巢癌的共识声明。
主要发现
- 共识识别了复发性卵巢癌临床试验的三个重要问题:亚组划分、对照臂选择与终点设置。
关键数值与推荐
- 治疗间歇(TFI)可细分为TFIp(即PFI)、TFInp(非PFI)和TFIb(生物制剂间歇)。
- 亚组划分还需考虑组织学、BRCA突变状态、既往治疗的数量与类型、既往手术结果及患者报告症状。
- 铂类为最佳选择时,对照臂应为含铂治疗联合或不联合抗血管生成药或PARP抑制剂。
- 铂类非最佳选择时,对照臂可包括非铂药物,单药或联合使用。
- 预期中位总生存期≤12个月的患者队列首选总生存期作为终点;预期中位总生存期>12个月时首选无进展生存期。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This manuscript reports the consensus statements regarding recurrent ovarian cancer (ROC), reached at the fifth Ovarian Cancer Consensus Conference (OCCC), which was held in Tokyo, Japan, in November 2015. Three important questions were identified: (i) What are the subgroups for clinical trials in ROC? The historical definition of using platinum-free interval (PFI) to categorise patients as having platinum-sensitive/resistant disease was replaced by therapy-free interval (TFI). TFI can be broken down into TFIp (PFI), TFInp (non-PFI) and TFIb (biological agent-free interval). Additional criteria to consider include histology, BRCA mutation status, number/type of previous therapies, outcome of prior surgery and patient reported symptoms. (ii) What are the control arms for clinical trials in ROC? When platinum is considered the best option, the control arm should be a platinum-based therapy with or without an anti-angiogenic agent or a poly (ADP-ribose) polymerase (PARP) inhibitor. If platinum is not considered the best option, the control arm could include a non-platinum drug, either as single agent or in combination. (iii) What are the endpoints for clinical trials in ROC? Overall survival (OS) is the preferred endpoint for patient cohorts with an expected median OS < or = 12 months. Progression-free survival (PFS) is an alternative, and it is the preferred endpoint when the expected median OS is > 12 months. However, PFS alone should not be the only endpoint and must be supported by additional endpoints including pre-defined patient reported outcomes (PROs), time to second subsequent therapy (TSST), or time until definitive deterioration of quality of life (TUDD).
引用
- Wilson MK, Pujade-Lauraine E, Aoki D, et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2017. PMID: 27993805. doi:10.1093/annonc/mdw663
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。